Anti-DLL4 VNAR targeted nanoparticles for targeting of both tumour and tumour associated vasculature

Adam  Leach; Peter Smyth; Laura Ferguson; John Steven; Michelle K. Greene; Cristina M.  Branco; Aidan P.  McCann; Andrew Porter; Caroline Jane Barelle; Christopher J. Scott

doi:10.1039/D0NR02962A

Anti-DLL4 VNAR targeted nanoparticles for targeting of both tumour and tumour associated vasculature

Adam Leach, Peter Smyth, Laura Ferguson, John Steven, Michelle K. Greene, Cristina M. Branco, Aidan P. McCann, Andrew Porter, Caroline Jane Barelle^* (Corresponding Author), Christopher J. Scott^* (Corresponding Author)

^*Corresponding author for this work

Medical Sciences

Research output: Contribution to journal › Article › peer-review

13 Citations (Scopus)

5 Downloads (Pure)

Abstract

Whilst there is an extensive body of preclinical nanomedicine research, translation to clinical settings has been slow. Here we present a novel approach to the targeted nanoparticle (NP) concept: utilizing both a novel targeting ligand, VNAR (Variable New Antigen Receptor), a shark-derived single chain binding domain, and an under-investigated target in delta-like ligand 4 (DLL4). We describe the development of an anti-DLL4 VNAR and the site-specific conjugation of this to poly(lactic-co-glycolic) acid PEGylated NPs using surface maleimide functional groups. These nanoconjugates were shown to specifically bind DLL4 with high affinity and were preferentially internalized by DLL4-expressing pancreatic cancer cell lines and endothelial cells. Furthermore, a distinct anti-angiogenic effect endowed by the anti-DLL4 VNAR was evident in in vitro tubulogenic assays. Taken together these findings highlight the potential of anti-DLL4 targeted polymeric NPs as a novel therapeutic approach in pancreatic cancer.

Original language	English
Pages (from-to)	14751-14763
Number of pages	13
Journal	Nanoscale
Volume	12
Issue number	27
Early online date	29 Jun 2020
DOIs	https://doi.org/10.1039/D0NR02962A
Publication status	Published - 21 Jul 2020

Bibliographical note

Acknowledgements
The authors acknowledge the Engineering and Physical Sciences Research Council (EPSRC) (S3802ASA) and the generous support of the Martin Family Foundation for funding the Ph.D. studentships of P. S. and A. L., respectively. This work was also partially funded through a US-Ireland R&D Partnership grant awarded by HSCNI (STL/5010/14), Medical Research Council UK (MC_PC_15013), and the Biotechnology and Biological Sciences Research Council (BBSRC) (BB/R009112/1).

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1039/D0NR02962ALicence: CC BY-NC

Leach_etal_Nano_AntiDLL4_VOR
This article is Open Access https://creativecommons.org/licenses/by-nc/4.0/
Final published version, 3.26 MBLicence: CC BY-NC

Cite this

@article{d09212ef7246469283e31f69a3f153d3,

title = "Anti-DLL4 VNAR targeted nanoparticles for targeting of both tumour and tumour associated vasculature",

abstract = "Whilst there is an extensive body of preclinical nanomedicine research, translation to clinical settings has been slow. Here we present a novel approach to the targeted nanoparticle (NP) concept: utilizing both a novel targeting ligand, VNAR (Variable New Antigen Receptor), a shark-derived single chain binding domain, and an under-investigated target in delta-like ligand 4 (DLL4). We describe the development of an anti-DLL4 VNAR and the site-specific conjugation of this to poly(lactic-co-glycolic) acid PEGylated NPs using surface maleimide functional groups. These nanoconjugates were shown to specifically bind DLL4 with high affinity and were preferentially internalized by DLL4-expressing pancreatic cancer cell lines and endothelial cells. Furthermore, a distinct anti-angiogenic effect endowed by the anti-DLL4 VNAR was evident in in vitro tubulogenic assays. Taken together these findings highlight the potential of anti-DLL4 targeted polymeric NPs as a novel therapeutic approach in pancreatic cancer.",

author = "Adam Leach and Peter Smyth and Laura Ferguson and John Steven and Greene, {Michelle K.} and Branco, {Cristina M.} and McCann, {Aidan P.} and Andrew Porter and Barelle, {Caroline Jane} and Scott, {Christopher J.}",

note = "Acknowledgements The authors acknowledge the Engineering and Physical Sciences Research Council (EPSRC) (S3802ASA) and the generous support of the Martin Family Foundation for funding the Ph.D. studentships of P. S. and A. L., respectively. This work was also partially funded through a US-Ireland R&D Partnership grant awarded by HSCNI (STL/5010/14), Medical Research Council UK (MC_PC_15013), and the Biotechnology and Biological Sciences Research Council (BBSRC) (BB/R009112/1).",

year = "2020",

month = jul,

day = "21",

doi = "10.1039/D0NR02962A",

language = "English",

volume = "12",

pages = "14751--14763",

journal = "Nanoscale",

issn = "2040-3364",

publisher = "Royal Society of Chemistry",

number = "27",

}

TY - JOUR

T1 - Anti-DLL4 VNAR targeted nanoparticles for targeting of both tumour and tumour associated vasculature

AU - Leach, Adam

AU - Smyth, Peter

AU - Ferguson, Laura

AU - Steven, John

AU - Greene, Michelle K.

AU - Branco, Cristina M.

AU - McCann, Aidan P.

AU - Porter, Andrew

AU - Barelle, Caroline Jane

AU - Scott, Christopher J.

N1 - Acknowledgements The authors acknowledge the Engineering and Physical Sciences Research Council (EPSRC) (S3802ASA) and the generous support of the Martin Family Foundation for funding the Ph.D. studentships of P. S. and A. L., respectively. This work was also partially funded through a US-Ireland R&D Partnership grant awarded by HSCNI (STL/5010/14), Medical Research Council UK (MC_PC_15013), and the Biotechnology and Biological Sciences Research Council (BBSRC) (BB/R009112/1).

PY - 2020/7/21

Y1 - 2020/7/21

N2 - Whilst there is an extensive body of preclinical nanomedicine research, translation to clinical settings has been slow. Here we present a novel approach to the targeted nanoparticle (NP) concept: utilizing both a novel targeting ligand, VNAR (Variable New Antigen Receptor), a shark-derived single chain binding domain, and an under-investigated target in delta-like ligand 4 (DLL4). We describe the development of an anti-DLL4 VNAR and the site-specific conjugation of this to poly(lactic-co-glycolic) acid PEGylated NPs using surface maleimide functional groups. These nanoconjugates were shown to specifically bind DLL4 with high affinity and were preferentially internalized by DLL4-expressing pancreatic cancer cell lines and endothelial cells. Furthermore, a distinct anti-angiogenic effect endowed by the anti-DLL4 VNAR was evident in in vitro tubulogenic assays. Taken together these findings highlight the potential of anti-DLL4 targeted polymeric NPs as a novel therapeutic approach in pancreatic cancer.

AB - Whilst there is an extensive body of preclinical nanomedicine research, translation to clinical settings has been slow. Here we present a novel approach to the targeted nanoparticle (NP) concept: utilizing both a novel targeting ligand, VNAR (Variable New Antigen Receptor), a shark-derived single chain binding domain, and an under-investigated target in delta-like ligand 4 (DLL4). We describe the development of an anti-DLL4 VNAR and the site-specific conjugation of this to poly(lactic-co-glycolic) acid PEGylated NPs using surface maleimide functional groups. These nanoconjugates were shown to specifically bind DLL4 with high affinity and were preferentially internalized by DLL4-expressing pancreatic cancer cell lines and endothelial cells. Furthermore, a distinct anti-angiogenic effect endowed by the anti-DLL4 VNAR was evident in in vitro tubulogenic assays. Taken together these findings highlight the potential of anti-DLL4 targeted polymeric NPs as a novel therapeutic approach in pancreatic cancer.

UR - http://www.scopus.com/inward/record.url?scp=85088264245&partnerID=8YFLogxK

U2 - 10.1039/D0NR02962A

DO - 10.1039/D0NR02962A

M3 - Article

SN - 2040-3364

VL - 12

SP - 14751

EP - 14763

JO - Nanoscale

JF - Nanoscale

IS - 27

ER -

Anti-DLL4 VNAR targeted nanoparticles for targeting of both tumour and tumour associated vasculature

Abstract

Bibliographical note

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this